Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1986 Nov;22(5):595–602. doi: 10.1111/j.1365-2125.1986.tb02940.x

A comparative study on the ventilatory and haemodynamic effects of xamoterol and atenolol in asthmatic patients.

J W Lammers, M E Müller, H T Folgering, C L van Herwaarden
PMCID: PMC1401187  PMID: 2878680

Abstract

The effects of single oral doses of atenolol 50 mg and xamoterol 200 mg (a recently developed partial beta 1-adrenoceptor agonist) on lung function, heart rate and blood pressure were investigated in 11 patients with asthma. Xamoterol caused a significant increase in heart rate and systolic blood pressure, which changes are consistent with the partial beta 1-adrenoceptor agonist activity of this drug. Atenolol induced a significant decrease in FEV1 and the forced vital capacity (FVC); there was a non-significant change in FEV1 and FVC after xamoterol. There was no significant difference between the effects of atenolol and xamoterol of FEV1 and FVC. Bronchospasm induced by atenolol 50 mg and xamoterol 200 mg was completely reversed by inhalation of the beta 2-adrenoceptor agonist terbutaline to a cumulative dose of 4.0 mg.

Full text

PDF
595

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Connolly C. K. Diurnal rhythms in airway obstruction. Br J Dis Chest. 1979 Oct;73(4):357–366. [PubMed] [Google Scholar]
  2. Cook N., Richardson A., Barnett D. B. Comparison of the beta 1 selective affinity of prenalterol and corwin demonstrated by radioligand binding. Eur J Pharmacol. 1984 Mar 2;98(3-4):407–412. doi: 10.1016/0014-2999(84)90289-9. [DOI] [PubMed] [Google Scholar]
  3. Ellis M. E., Sahay J. N., Chatterjee S. S., Cruickshank J. M., Ellis S. H. Cardioselectivity of atenolol in asthmatic patients. Eur J Clin Pharmacol. 1981;21(3):173–176. doi: 10.1007/BF00627916. [DOI] [PubMed] [Google Scholar]
  4. Fleming G. M., Chester E. H., Schwartz H. J., Jones P. K. Beta-adrenergic blockade of the lung. Dose-dependent cardioselectivity of tolamolol in asthma. Chest. 1978 Jun;73(6):807–812. doi: 10.1378/chest.73.6.807. [DOI] [PubMed] [Google Scholar]
  5. Greefhorst A. P., van Herwaarden C. L. Comparative study of the ventilatory effects of three beta 1-selective blocking agents in asthmatic patients. Eur J Clin Pharmacol. 1981;20(6):417–421. doi: 10.1007/BF00542093. [DOI] [PubMed] [Google Scholar]
  6. Greefhorst A. P., van Herwaarden C. L. Ventilatory and haemodynamic effects of prenalterol and terbutaline in asthmatic patients. Eur J Clin Pharmacol. 1983;24(2):173–178. doi: 10.1007/BF00613813. [DOI] [PubMed] [Google Scholar]
  7. Lammers J. W., Folgering H. T., van Herwaarden C. L. Ventilatory effects of atenolol and bevantolol in asthma. Clin Pharmacol Ther. 1985 Oct;38(4):428–433. doi: 10.1038/clpt.1985.199. [DOI] [PubMed] [Google Scholar]
  8. Lammers J. W., Folgering H. T., van Herwaarden C. L. Ventilatory effects of beta 1-receptor-selective blockade with bisoprolol and metoprolol in asthmatic patients. Eur J Clin Pharmacol. 1984;27(2):141–145. doi: 10.1007/BF00544036. [DOI] [PubMed] [Google Scholar]
  9. Löfdahl C. G., Svedmyr N. Effect of prenalterol in asthmatic patients. Eur J Clin Pharmacol. 1982 Oct;23(4):297–302. doi: 10.1007/BF00613609. [DOI] [PubMed] [Google Scholar]
  10. MCNEILL R. S. EFFECT OF A BETA-ADRENERGIC-BLOCKING AGENT, PROPRANOLOL, ON ASTHMATICS. Lancet. 1964 Nov 21;2(7369):1101–1102. doi: 10.1016/s0140-6736(64)92617-0. [DOI] [PubMed] [Google Scholar]
  11. Melander A., Danielson K., Scherstén B., Wåhlin E. Enhancement of the bioavailability of propranolol and metoprolol by food. Clin Pharmacol Ther. 1977 Jul;22(1):108–112. doi: 10.1002/cpt1977221108. [DOI] [PubMed] [Google Scholar]
  12. Newman S. P., Morén F., Pavia D., Little F., Clarke S. W. Deposition of pressurized suspension aerosols inhaled through extension devices. Am Rev Respir Dis. 1981 Sep;124(3):317–320. doi: 10.1164/arrd.1981.124.3.317. [DOI] [PubMed] [Google Scholar]
  13. Nuttall A., Snow H. M. The cardiovascular effects of ICI 118,587: A beta 1-adrenoceptor partial agonist. Br J Pharmacol. 1982 Oct;77(2):381–388. doi: 10.1111/j.1476-5381.1982.tb09309.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. O'Neill P. A., Morton P. B., Sharman P., Marlow H. F., Stark R. D. The effects of ICI 118,587 and atenolol on the responses to exercise and on breathlessness in healthy subjects. Br J Clin Pharmacol. 1984 Jan;17(1):37–41. doi: 10.1111/j.1365-2125.1984.tb04996.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Perks W. H., Chatterjee S. S., Croxson R. S., Cruickshank J. M. Comparison of atenolol and oxprenolol in patients with angina or hypertension and co-existent chronic airways obstruction. Br J Clin Pharmacol. 1978 Feb;5(2):101–106. doi: 10.1111/j.1365-2125.1978.tb01608.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Rousseau M. F., Pouleur H., Vincent M. F. Effects of a cardioselective beta 1 partial agonist (corwin) on left ventricular function and myocardial metabolism in patients with previous myocardial infarction. Am J Cardiol. 1983 May 1;51(8):1267–1274. doi: 10.1016/0002-9149(83)90297-7. [DOI] [PubMed] [Google Scholar]
  17. Rugg E. L., Barnett D. B., Nahorski S. R. Coexistence of beta1 and beta2 adrenoceptors in mammalian lung: evidence from direct binding studies. Mol Pharmacol. 1978 Nov;14(6):996–1005. [PubMed] [Google Scholar]
  18. Zaagsma J., van der Heijden P. J., van der Schaar M. W., Bank C. M. Comparison of functional beta-adrenoceptor heterogeneity in central and peripheral airway smooth muscle of guinea pig and man. J Recept Res. 1983;3(1-2):89–106. doi: 10.3109/10799898309041925. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES